Pasithea Therapeutics (KTTA): Director received 33K shares
Emer Leahy, Director at Pasithea Therapeutics, reported a grant / award of 33K shares.
- 33K
- Shares · @ $0.75
- Traded
- Nov 28, 2025
- Filed
- Dec 1, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 24, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 24, 2025, the Board of Directors (the “Board”) of Pasithea Therapeutics Corp. (the “Company”) approved the following compensation arrangements for the Company’s executive officers and directors.”
- Nov 28, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
- Nov 28, 2025Insider · 3 peopleInsiders: 3 purchases (~$150K)
What came next
- Jan 28, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On January 28, 2026, at a Special Meeting of Stockholders (the “Special Meeting”) of Pasithea Therapeutics Corp. (the “Company”), the Company’s stockholders approved an amendment (the “Plan Amendment”) to the Company’s 2023 Stock Incentive Plan, as amended (the “2023 Incentive Plan”), increasing the number of shares authorized for issuance under the 2023 Incentive Plan by 11,985,779 shares to 14,000,000 shares.”
- Feb 20, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On February 20, 2026, Pasithea Therapeutics Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).”
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Pasithea Therapeutics
For Pasithea Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KTTA page.
How this filing works
Explore the data
Common questions
Which Pasithea Therapeutics (KTTA) insider traded, and how much?
Emer Leahy, Director at Pasithea Therapeutics, reported a grant / award of 33K shares. At $0.75.
When did it happen, and when was it made public?
Traded: Nov 28, 2025. Filed: Dec 1, 2025. That is 3 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Pasithea Therapeutics recently?
For Pasithea Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the KTTA page.
Does this mean KTTA stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Pasithea Therapeutics
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Schedule 13GNov 16, 2026
- SEC Schedule 13GNov 6, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its KTTA page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
